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ABSTRACT
Targeted expression of genes coding for proteins specific to astrocytes, oligodendrocytes and myelin
10 was performed in frontal cortex area 8 of Creutzfeldt-Jakob disease methionine/methionine and
valine/valine (CJD MM1 and VV2, respectively) compared with controls. GFAP (glial fibrillary acidic
protein) mRNA was up-regulated whereas SLC1A2 (solute carrier family 1 member 2, coding for
glutamate transporter 1: GLT1), AQ4 (aquaporin 4), MPC1 (mitochondrial pyruvate carrier 1) and
UCP5 (mitochondrial uncoupled protein 5) mRNAs were significantly down-regulated in CJD MM1
15 and CJD VV2, and GJA1 (connexin 43) in CJD VV2. OLIG1 and OLIG2 (oligodendocyte transcription
factor 1 and 2, respectively), SOX10 (SRY-Box10) and oligodendroglial precursor cell (OPC) marker NG2
(neuronal/glial antigen) 2 were preserved, but GALC (coding for galactosylceramidase), SLC2A1 (solute
carrier family 2 member 1: glucose transporter member 1: GLUT1) and MCT1 (monocarboxylic acid
transporter 1) mRNA expression levels were significantly reduced in CJD MM1 and CJD VV2.
20 Expression levels of most genes linked to myelin were not altered in the cerebral cortex in CJD.
Immunohistochemistry to selected proteins disclosed individual variations but GFAP, Olig-2, AQ4 and
GLUT1 correlated with mRNA levels, whereas GLT1 was subjected to individual variations. However,
MPC1, UCP5 and MCT1 decrease was more closely related to the respective reduced neuronal
immunostaining. These observations support the idea that molecular deficits linked to energy
25 metabolism and solute transport in astrocytes and oligodendrocytes, in addition to neurons, are
relevant in the pathogenesis of cortical lesions in CJD.
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Introduction
Prion diseases are a group of transmissible encephalo-
30 pathies linked to the prion protein (PrPC) which is
converted into an abnormally conformed proteinase
K-resistant protein named prion (PrPSC). The human
prion diseases are sporadic, iatrogenic and genetic
Creutzfeld-Jakob disease (sCJD, iCJD and gCJD,
35 respectively), Gerstmann-Straüsler-Scheinker disease
(GSS) disease, and fatal familial insomnia (FFI). gCJD,
GSS and FFI are due to mutations in prion protein gene
(PRNP) [1–7]. The main prionopathies in animals are
scrapie (typical and atypical) in sheep and goats;
40 chronic wasting disease in deer, elk, moose and rein-
deer; and bovine spongiform encephalopathy (BSE) in
cattle [8].Variant CJD (vCJD) is considered a form of
BSE transmitted to humans [9]. CJD is not homoge-
neous; different subtypes are distinguished in sCJD
45 depending on the prion type (I and 2) and the compo-
sition of codon 129 in PRNP (methionine/methionine:
MM, valine/valine: VV, and methionine/valine: MV),
each one with singular clinical phenotypes [10,11]. The
most frequent subtypes are sCJD MM1 and sCJD VV2.
50Common neuropathological lesions in CJD are neu-
ron loss, spongiform change and deposition of PrPSC.
Additional characteristics of sCJD MM1 are microva-
cuolar spongiform change in the frontal and occipital
cortices, and molecular layer of the cerebellum, and
55synaptic-like PrPSC deposition. Particular features of
sCJD VV2 are microvacuolar or confluent spongiform
change, major involvement of the cerebellum, and
synaptic, perineuronal and plaque-like PrPSC deposits
[4–7]. Reactive astrocytosis and microgliosis, accompa-
60nied by a robust molecular inflammatory response, are
important accompanying features [12–15].
Besides their contribution to astrocytic gliosis and
inflammation, little is known about the defects of astro-
cytes in CJD. In addition to neuronal bodies, dendrites,
65synapses and axons, PrPSC can be present in astrocytes
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and microglia [16]. Aquaporin 1 and 4 immunoreactiv-
ity is increased [17,18], thus suggesting adaptation to
water transport. Moreover, recent studies have shown
that human astrocytes have the capacity to take up and
70 degrade normal and protease-resistant prion protein
[19] and that they can transfer PrPSC to neurons via
nanotubules [20] thereby contributing to prion disease
progression.
Regarding oligodendrocytes, less information is
75 available in CJD. Oligodendrocytes are apparently resis-
tant to PrPSC infectivity [21]. However, axon and mye-
lin damage occurs in prion diseases [22], abnormal
interactions between oligodendroglia and astrocytes
are found in experimental CJD and scrapie [23], and
80 engulfment of oligodendrocytes by hypertrophic astro-
cytes has been reported in the white matter in CJD [24].
PRPSC is also localized as arrays adjacent to myelin
fibers in the cerebrum and cerebellum in CJD [25].
Based on these data, the present study was under-
85 taken to gain understanding about transcription altera-
tion of genes encoding proteins specifically expressed in
astrocytes and oligodendrocytes in frontal cortex area 8
of CJD MM1 and CJD VV2. Selected genes include
those encoding structural proteins of astrocytes and
90 myelin, those involved in energy metabolism and
axon maintenance, and genes of connexins of the gap
junctions between oligodendrocytes and astrocytes.
Protein expression of altered has been assessed by
immunohistochemistry.
95 Results
Astrocytic markers
Covariance analysis (ANCOVA) of GFAP (coding for glial
fibrillary acidic protein)mRNA expression levels revealed a
significant group effect [F(2,19) = 4.383, P = 0.027] but did
100 not show RIN effect [F(1,19) = 0.337, P = 0.568].
Subsequent one-way ANOVA analysis [F(2,20) = 7.918,
P = 0.0029] revealed significant increase in CJD MM1 and
CJD VV2 when compared with controls (P = 0.012 and
P = 0.005, respectively). In contrast, ANCOVA of
105 ALDH1L1 (coding for aldehyde dehydrogenase 1, family
member L1)mRNA, used asmarker of total astrocytes, had
non-significant group [F(2,22) = 1.087, P = 0.355] and RIN
[F(1,22) = 0.021, P = 0.887] effects; no differences of
ALDH1L1 mRNA were observed between CJD and con-
110 trols. ANCOVA of AQP4 (coding for aquaporin 4) mRNA
showed significant group effect [F(2,21) = 4.307, P = 0.027]
but not RIN effect [F(1,21) = 0.334, P = 0.569]. Subsequent
one-way ANOVA analysis [F(2,22) = 8.596, P = 0.0017]
showed significant decreased expression in CJD MM1 and
115 CJD VV2 when compared with controls (P = 0.26 and
P = 0.002, respectively). ANCOVA analysis of SLC1A2
(coding for glutamate transporter 1) mRNA expression
showed significant group effect [F(2,21) = 6.031,
P = 0.009] but not RIN effect [F(3,25) = 0.754, P = 0.395].
120One-way ANOVA analysis [F(1,21) = 8.865, P = 0.0015]
revealed significant down-regulation reduction of SLC1A2
in CJD VV2 when compared with controls (P = 0.001) and
with CJD MM1 (P = 0.028).
ANCOVA of MCT4 (coding for solute carrier family
125member 16: monocarboxylic acid transporter member 4)
mRNA expression revealed no significant changes with
respect to group [F(2,20) = 2.110, P = 0.147] and RIN
[F (1,20) = 0.195, P = 0.664] effect. Conversely, ANCOVA
ofMPC1 (coding for mitochondria pyruvate carrier 1) and
130UCP5 (coding for mitochondrial anion carrier, mitochon-
drial uncoupling protein 5) showed significant group effect
[F(2,21) = 6.282,P= 0.007] and [F(2,21) = 9.103,P= 0.001],
respectively, as well as RIN effect [F(1,21) = 4.972,
P = 0.037] and [F(1,21) = 8.734, P = 0.008], respectively.
135Next, ANCOVA revealed significantly decreased expres-
sion of MPC1 and UCP5 in CJD MM1 (P = 0.019 and
P = 0.008 respectively) and CJD VV2 (P = 0.002 and
P = 0.00�1, respectively) when compared with controls.
ANCOVA of UCP4 mRNA (coding for mitochondrial
140uncoupling protein 4) did not reveal significant alterations
related to group [F(2,20) = 0.009, P = 0.991] but to RIN
effects [F(1,20) = 11.258, P = 0.003].
Finally, the expression of GJB6 (coding for connexin
30), which was preserved (although with a trend to
145decrease in CJD VV2), was not dependent on group
[F(2,19) = 2.418, P = 0.113] or RIN [F(1,19) = 1.158,
P = 0.294] effect. ANCOVA of GJA1 (coding for
connexin 43) mRNA expression indicated significant
group effect [F(2,21) = 8.218, P = 0.002] but not RIN
150effect [F(1,21) = 4.105, P = 0.056]. Subsequent one-way
ANOVA analysis [F(2,22) = 8.224, P = 0.002] revealed
significantly reduced GJA1 expression in CJD VV2
when compared with controls (P = 0.007) and with
CJD MM1 (P = 0.004) (Figure 1(a)).
155Oligodendrocytic markers
ANCOVA showed no group or RIN effect on mRNA
expression levels of the oligodendroglial markers OLIG1
[F(2,23) = 0.221, P = 0.804] and [F(1,23) = 0.336,
P = 0.568], OLIG2 [F(2,23) = 0.801, P = 0.461] and [F
160(1,23) = 0.276, P = 0.604], and SOX10 [F(2,23) = 1.369,
P = 0.274] and [F(1,23) = 3.930, P = 0.059]; and the OPC
marker NG2 [F(2,23) = 0.412, P = 0.667] and [F
(1,23) = 0.001, P = 0.978]. Expression levels of OLIG1,
OLIG2 and NG2 were similar in CJD and controls.
165Likewise, ANCOVA showed no alterations in the
expression levels of genes coding for different myelin
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proteins, such as MYRF (coding for myelin regula-
tory factor), MBP (coding for myelin basic protein),
PLP1 (coding for proteolipid protein 1), MAL
170 (coding for Mal), MOG (myelin oligodendrocyte gly-
coprotein) and MOBP (myelin-associated oligoden-
drocyte basic protein) due to group effect [F
(2,23) = 2.692, P = 0.0.89], [F(2,22) = 2.214,
P = 0.133], [F(2,23) = 2.356, P = 0.117], [F
175 (2,23) = 3.373, P = 0.052], [F(2,23) = 3.146,
P = 0.062] and [F(2,23) = 2.409, P = 0.112], respec-
tively, or due to RIN effect [F(1,23) = 3.664,
P = 0.068], [F(1,22) = 0.918, P = 0.349], [F
(1,23) = 0.991, P = 0.330], [F(1,23) = 0.311,
180 P = 0.582], [F(1,23) = 1.968, P = 0.174] and [F
(1,23) = 3.916, P = 0.060], respectively. However,
ANCOVA analysis revealed significant group effect
on CNP (coding for 2ʹ,3ʹ-cyclic nucleotide 3ʹ phos-
phodiesterase) and MAG (myelin associated glyco-
185protein) mRNA expression [F(2,21) = 3.970,
P = 0.034] and [F(2,22) = 3.786, P = 0.039], respec-
tively; but not RIN effect [F(1,21) = 1.697, P = 0.207],
[F(1,22) = 3.307, P = 0.083], respectively. Subsequent
analysis revealed no differences in CNP [F
190(2,22) = 2.328, P = 0.12] and MAG [KG
(2,23) = 5.391, P = 0.0675] mRNA expression levels
between CJD and controls. Regarding GALC (coding
for galactosylceramidase), covariance analysis showed
a significant effect of group [F(2,21) = 12.680,
195P = 0.000] and RIN [F(1,21) = 10.171, P = 0.004].
ANCOVA’s contrast analysis revealed significant
GALC mRNA down-regulation in CJD MM1 and
CJD VV2 (P = 0.001 and P = 0.000, respectively).
Figure 1. Expression levels, as revealed by RT-qPCR, of genes coding for specific proteins of astrocytes (a) and oligodendrocytes (b)
in frontal cortex area 8 of CJD MM1 and CJD VV2 compared with expression levels in controls. Statistical analysis of the expression
data between groups uses one-way analysis of variance (ANOVA) followed by Tukey post-test for GFAP, AQP4, SLC1A2, MPC1, UCP4,
GJB6, GJA1, OLIG1, OLIG2, NG2, CNP, MAL, GALC, MCT1, GJB1 and GJC2. Kruskal-Wallis test followed by Dunns post-hoc test was used
for ALDH1L1, MCT4, UCP5, SOX10, MYRF, MBP, PLP1, MAG, MOG, MOBP, SLC2A1 and CLDN11 (SPSS software. IBM SPSS Statistics for
Windows, Version 21.0). All data are expressed as mean ± SEM. Differences between groups are considered statistically significant at
* P < 0.05, ** P < 0.01, *** P < 0.001 when comparing CJD cases with controls; and set at $ P < 0.05 and $$ P < 0.01 when
comparing CJD MM1 with CJD VV2.
PRION 3
ANCOVA applied to expression levels of SLC2A1
200 (coding for solute carrier family 2: glucose transporter,
member 1) and MCT1 (coding for solute carrier family
16: monocarboxylic acid transporter, member 1)
revealed significant group effect [F(2,22) = 9.304,
P = 0.001] and [F(2,21) = 3.468, P = 0.050], respec-
205 tively; but no RIN effect [F(1,22) = 0.034, P = 0.855]
and [F(1,21) = 3.924, P = 0.061], respectively. Post-
variance analysis of SLC2A1 and MCT1 ([KG
(2,23) = 15.26, P = 0.0005] and [F(2,22) = 11.333,
P = 0.000], respectively) showed significant SLC2A1
210 and MCT1 decrease in CJD MM1 (P = 0.01 and
P = 0.04, respectively) and CJD VV2 (P = 0.01 and
P = 0.001, respectively) when compared with control
group.
Finally, ANCOVA of expression of genes coding for
215 connexins 32 and 47 (GJB1 and GJC2), and claudin 11
(CLDN11) did not reveal significant group [F
(2,22) = 3.271, P = 0.057], [F(2,23) = 2.461,
P = 0.107] and [F(2,23) = 2.608, P = 0.095], and RIN
[F(1,22) = 1.326, P = 0.262], [F(1,23) = 0.730,
220 P = 0.402] and [F(1,23) = 0.719, P = 0.405] effects,
respectively. GJB1, GJC2 and CLDN11 expression was
not modified in CJD, although there was a trend to
decrease in CJD MM1, when compared with controls
(Figure 1(b)).
225Immunohistochemistry
Paraffin sections processed for immunohistochemistry
showed marked increase in GFAP immunoreactivity in
CJD when compared with controls, as expected. GFAP-
immunoreacytive astrocytes were increased in number,
230and the amount of GFAP was increased per astrocyte
with robust immunostaining of astrocyte processes
(Figure 2). In contrast, OLig-2 immunostaining in the
cerebral cortex did not reveal major differences
between CJD and controls (Figure 2). Aquaporin 4
235(AQP4) immunoreactive localized in astrocytes deli-
neating fine and varicose network processes in control
cerebral cortex. AQP4 immunoreactivity in CJD was
variable from one case to another yet preserving the
same morphological profile (Figure 2). In advanced
240cases, AQP4 immunoreactivity was increased and
blurred as reported elsewhere. GLT1 immunoreactivity
in control cases was seen as delicate meshwork of fine
and varicose processes around the nuclei of astrocytes.
This pattern was preserved in CJD, although with
245marked differences from one case to another; in some
cases GLT1 immunoreactivity practically disappeared
in areas with severe spongiform change while it was
practically preserved in others; Moreover variations
were also observed in different areas in the same tissue
250section (Figure 2). MPC1 was mainly localized in the
Figure 2. Representative images of glial fibrillary acidic protein (GFAP), Olig-2, aquaporin 4 (AQP4), solute carrier family 1, member 1
(SLC1A2: glial affinity glutamate transporter: GLT1), mitochondrial pyruvate carrier 1 (MPC1), mitochondrial uncoupling protein 5
(UCP5), solute carrier family 2 member 1 (glucose transporter 1: GLUT1) and solute carrier family 16 member 1 (monocarboxylic acid
transporter 1: MCT1) immunoreactivity in the frontal cortex area 8 of controls and cases with CJD MM1. Paraffin sections processed
for immunohistochemistry and slightly stained with hematoxylin, bar = 25 μm.
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cytoplasm of neurons in the cerebral cortex of control
cases as a punctuate immunostaining consistent with a
mitochondrial localization. MPC1 immunoreactivity
was dramatically reduced in neurons in CJD but
255 increased in a few cortical glial cells (Figure 2).
Similarly, UPC5 immunostaining mainly decorated
neurons in controls. However, UPC5 immunoreactivity
decreased in neurons but increased in glial cells, mainly
in cells with astrocyte morphology, in CJD (Figure 2).
260 GLUT1 was mainly found in the walls of small blood
vessels consistent with endothelial localization as
expected. In addition, GLUT1 immunoractivity was
found as blurred patches in the cortical neuropil in
control cases; these patches were markedly reduced in
265 size and intensity in CJD (Figure 2). Finally, MCT1 was
mainly localized in endothelial cells and to a lesser
degree in neurons and glial cells in controls. Marked
reduction in MCT1 immunoractivity was found in
neurons and glial cells, but not in endothelial cells, in
270 CJD (Figure 2).
Discussion
The present study is focused on astrocytes and oligo-
dendrocytes of the frontal cortex area 8 in CJD MM1
and VV2 compared to controls. In spite of the opti-
275 cally-monitored separation of the cerebral cortex from
the underlying white matter, contamination by subcor-
tical U fibers cannot be ruled out in our study. This is
convenient remark as astrocytes and oligodendrocytes
in grey matter differ from astrocytes and oligodendro-
280 cytes in white matter, and from one region to another.
Astrogliosis is one of the characteristic neuropatho-
logical lesions in cerebral cortex CJD which is here
manifested by increased significant GFAP mRNA
expression, as previously reported [15]. However, no
285 significant differences are seen in the expression levels
of the gene coding for aldehyde dehydrogenase 1 family
member L1 (ALDH1L1) used as a marker of the total
astrocyte population. Aquaporin 4 protein levels, as
revealed by gel electrophoresis and western blotting,
290 are markedly increased in CJD [17]. This is in contrast
with the down-regulation of AQP4 mRNA in CJD
MM1 and CJD VV2, here observed. Yet, AQP4 immu-
noreactivity is variable from one case to another:
AQP4 immunorecativity is apparently decreased in
295 some cases, increased in others, and even increased and
blurred in cases with severe spongiform change. We do
not have an explanation for this point; enhanced trans-
lation and/or reduced degradation can account for dis-
crepancies between mRNA and protein expression, and
300 for case-to-case and area differences in protein immu-
noreactivity. Expression of solute carrier family 1A2
(SLC1A2: GLT1) is reduced in CJD VV2, pointing to
the possibility of unbalanced glutamate concentrations
between neurons and astrocytes in certain forms of
305CJD. However, immunohistochemistry reveals indivi-
dual variations and areal variations in GLT1 expression
in the same tissue section. Therefore, further studies in
animal models are needed to evaluate GLT1 mRNA
and protein expression in prion diseases.
310In addition to these aspects, new information has
been obtained in this study. Present quantitative data
show altered expression of several genes coding for key
specific proteins of astrocytes and oligodendrocytes in
frontal cortex area 8 in CJD which may have functional
315implications in the pathogenesis of the disease.
Reduced expression of mitochondrial pyruvate carrier
1 (MPC1) and mitochondrial uncoupling protein 5
(UCP5, SLC25A14, BMCP1: brain mitochondrial
uncoupling protein 1) suggest altered mitochondrial
320function in CJD MM1 and CJD VV2. Reduced expres-
sion of solute carrier family 2A1 (SLC2A1 or GLUT1)
points to altered glucose transport, whereas reduced
expression of solute carrier family 16 (MCT1) suggests
impaired monocarboxylic acid transport. These are
325important aspects as blood-derived glucose through
GLUT1 is metabolized via glycolysis to produce piru-
vate and lactate which are delivered to the axons
through specific solute carriers, the monocarboxylase
transporters (MCTs) located in cell membranes [26,27].
330In glia, MCT1 is mainly expressed in developing oligo-
dendrocytes and MCT4 in astrocytes [28,29]. Inhibition
of MCT1 in organotypic cultures of the spinal cord in
glucose-deprived media is toxic to neurons; the effects
on neurons are reversed with the addition of lactate
335into the medium [29]; moreover, reduction of MCT1
activity in vivo results in axonal damage [29].
These changes are not accompanied by altered expres-
sion of oligodendroglial markers OLIG1, OLIG2 and
SOX10 [30]; and adult oligodendroglial precursors
340(NG2) [31,32]. The expression of genes encoding main
myelin proteins is also preserved in frontal cortex in CJD,
includingmyelin basic protein (MBP), proteolipid protein
(PLP), 2ʹ,3ʹ-cyclic nucleotide-3ʹphosphodiesterase (CNP),
myelin-associated glycoprotein (MAG), myelin oligoden-
345drocyte glycoprotein (MOG) and myelin/oligodendrocyte
basic protein (MOBP) [33–35].The expression of
CLDN11, the gene encoding for claudin 11, principal
component of tight junctions of myelin connections at
their edges [36,37], is not modified in CJD. The expres-
350sion of MYRF, encoding myelin regulatory factor which
triggers myelination following binding to several promo-
ters of genes coding for myelin proteins [38], is main-
tained in CJD. In contrast, the expression of the gene
coding for galactocerebrosidase (GALC) is reduced in
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355 CJDMM1 and VV2, thus indicating possible impairment
in glycosphingolipid metabolism. To our knowledge,
most studies of brain lipids in CJD were carried out
many years ago and the main focus was on ganglioside
alterations [39–42]. Since the present studies are focused
360 on the cerebral cortex, further investigation is needed to
get information about brain lipid alterations in the white
matter in prion diseases.
Oligodendrocytes are connected with each other and
with astrocytes through gap junctions thus forming a
365 glial syncytium in the white matter tracts [43,44]. Gap
junctions are composed of connexins (Cx); Cx32 and
Cx47 are synthesized by oligodendrocytes, and Cx30 and
Cx43 by astrocytes [45]. The expression of genes coding
for Cx32 (GJB1) and Cx47 (GJC2), and Cx30 (GJB6) is
370 similar in CJD and in control cases, but GJA1 (encoding
Cx43) mRNA expression is reduced in CJD VV2 when
compared with controls and CJD MM1. Whether these
changes have implications in the normal function of the
glial syncitium deserves further attention.
375 Interpretation of some of the present data must be
taken with caution. MPC1 is expressed in brain [46]
principally in neurons in controls. MPC1 immunoreac-
tivity is reduced in neurons but increased in glial cells in
CJD. Therefore, the origin of decreased MPC1 mRNA
380 expression in CJD here observed may be due to damaged
neurons, whereas MPC1 protein is increased in glial cells.
Similarly, UC5P in the brain is mainly expressed in neu-
rons [47]; reduced UCP5 mRNA expression here
observed in CJD is accompanied by reduced UPC5
385 immunoreactivity in neurons, but this accompanied by
increased immunoreactivity in glial cells with the mor-
phology of astrocytes.
GLUT1 is largely expressed in red blood cells and
endothelial cells, including brain microvessels [48,49]. No
390 alterations in GLUT1 immunoreactivity is found in CJD
microvessels; reduction of GLUT1 mRNA correlates with
decreased GLUT1 immunoreactivity in the neuropil in
CJD. Finally, MCT1 is widely expressed in endothelial
cells in brain [50–52], but also in glial cells especially during
395 development [53,54]. MCT1 immunoreactivity in the adult
brain is also observed in neurons. MCT1 immunoractivity
is preserved in endothelial cells in CJD when compared
with controls; reduced MCT1 mRNA and protein in CJD
can be ascribed to reduced expression in neurons.
400 The concepts of astrocytopathy and oligodendrocyto-
pathy, referring to molecular alterations in astrocytes and
oligodendrocytes, are appropriate in neurodegenerative
diseases with abnormal protein aggregates [55–60]. This
study supports the idea that molecular flaws in astrocytes
405 and oligodendrocytes, in addition to neurons, are relevant
in the pathogenesis of cortical alterations in CJD.
Material and methods
Human cases
CJD cases were clinically diagnosed on the basis of rapid
410dementia together with variable accompanying symp-
toms, neuroimaging alterations and characteristic CSF
biomarkers; all of them were tested for homozygosity of
codon 129 in PRNP. Verification of clinical diagnosis
was obtained after post-mortem neuropathological study
415of the brain. Controls did not show neurological symp-
toms; moreover, cases with metabolic syndrome, auto-
immune diseases, fever and prolonged agonal state were
not included in this series. Brain samples were obtained
from the Brain Banks of the Institute of Neuropathology
420HUB-ICO-IDIBELL Biobank and the Hospital Clinic-
IDIBAPS Biobank following the guidelines of the
Spanish legislation on this matter and the approval of
the local ethics committees. The post-mortem interval
between death and tissue processing was between 2h
42545min and 22h 40min. One hemisphere was fixed by
immersion in 4% buffered formalin for 3 weeks. The
neuropathological study in control and CJD cases was
carried out on, at a minimum, twenty selected 4μm-thick
de-waxed paraffin sections of representative regions of
430the frontal, temporal, parietal, motor, primary visual,
anterior cingulate and entorhinal cortices, hippocampus,
amygdala, basal forebrain, caudate, putamen, globus pal-
lidus, thalamus, midbrain, pons, medulla oblongata, cer-
ebellar vermis, hilus and cerebral white matter. Sections
435were stained with haematoxylin and eosin, Klüver-
Barrera, or processed for immunohistochemistry for
microglia (Iba-1, Wako, Richmond, VA, USA), glial
acidic protein (GFAP, Dako, Gostrup, Denmark),
β-amyloid (Dako, clone 6F/3D), phospho-tau (Thermo
440Scientific, Rockford, USA, clone AT8), α-synuclein
(Novocastra, Newcastle, UK, clone KM51), TDP-43
(Abnova, Taipei, Taiwan, clone 2E2-D3), PrP (clon
3F4, Millipore, Darmstadt, GE) following proteinase K
incubation, ubiquitin (Dako, Polyclonal Rabbit) and p62
445(BD Biosciences, San Jose, USA, Purified Mouse Anti-
p62 LCK ligand) using EnVision+ System peroxidase
(Dako), and diaminobenzidine and H2O2.
Samples of the frontal cortex and cerebellum of the
other hemisphere were rapidly dissected, frozen on metal
450plates over dry ice and stored at −80ºC until use. Part of
this material was used for gel electrophoresis and western
blotting for identification of protease-resistant PrP type.
CJD was diagnosed following well-established neuro-
pathological criteria, codon 129 genotype and character-
455istics of PrP pattern on western blots [61]. None of the
cases had suffered from panencephalopathic CJD [62].
Additional brain pathology consisting of neurofibrillary
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tangles at stages I-II of Braak and Braak, argyrophilic
grain disease stage 2, mild small blood vessel disease,
460 and Lewy bodies in the brain stem in some individuals
were expected with the age of the patients. Similar lesions
were found in the control group and, therefore, they were
not contemplated as discriminating variables.
The whole series included 7 CJD MM1 (4 men and 3
465 women; age: 70.5 ± 5.5), 10 CJDVV2 (4men and 6women;
age 66.5 ± 6.85) and 10 controls (6 men and 4 women, age
67.1 ± 7.6). A summary of cases is shown in Table 1.
Biochemical studies were carried out in the frontal
cortex area 8 after our best optically-monitored dissec-
470 tion of the cerebral cortex and white matter. However,
inclusion of white matter subcortical U fibers cannot be
ruled out in the present study.
RNA purification
RNA from frozen frontal cortex area 8 was extracted fol-
475 lowing the instructions of the supplier (RNeasy Mini Kit,
Qiagen® GmbH, Hilden, Germany). RNA integrity and
28S/18S ratios were determined with the Agilent
Bioanalyzer (Agilent Technologies Inc, Santa Clara, CA,
USA). RIN values are shown in Table 1: control 6.76 ± 0.5;
480 CJD MM1 5.68 ± 0.8 and CJD VV2 5.84 ± 0.6). Samples
were treated with DNase digestion, and RNA concentra-
tion was evaluated using a NanoDrop™ Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA).
Rt-qPCR
485TaqMan RT-qPCR assays were performed in duplicate
for each gene on cDNA samples in 384-well optical
plates using an
AQ9
�ABI Prism 7900 Sequence Detection
system (Applied Biosystems, Life Technologies,
Waltham, MA, USA).�Probes are listed in Table II.
490For each 10μL TaqMan reaction, 4.5μL cDNA was
mixed with 0.5μL 20x TaqMan Gene Expression
Assays and 5μL of 2x TaqMan Universal PCR
Master Mix (Applied Biosystems). Values of GUS-β
were used as internal controls for normalization [63].
495The parameters of the reactions were 50°C for 2min,
95°C for 10min, and 40 cycles of 95°C for 15sec and
60°C for 1min. Finally, capture of all TaqMan PCR
data used the Sequence Detection Software (SDS ver-
sion 2.2.2, Applied Biosystems). For the data analysis,
500threshold cycle (CT) values for each sample were
processed to obtain the double delta CT (ΔΔCT)
values. First, delta CT (ΔCT) values were calculated
as the normalized CT values of each target gene in
relation to the CT of endogenous controls GUS-β.
505Then, ΔΔCT values were obtained from the ΔCT of
Table 1. Summary of cases M: man; W: woman; Age in years; CJD:
Creutzfeldt-Jakob disease, subtypes MM1 and VV2; PMD: post-mor-
tem delay; RIN: RNA integrity number.
Case Sex Age Diagnosis PMD RIN
1 M 66 Control 18 h 00 min 6.4
2 M 61 Control 03 h 40 min 7.0
3 M 74 Control 06 h 40 min 7.2
4 M 65 Control 05 h 15 min 6.8
5 M 63 Control 08 h 05 min 7,1
6 W 79 Control 03 h 35 min 6.8
7 W 67 Control 05 h 20 min 6,2
8 M 70 Control 03 h 45 min 7.2
9 M 52 Control 04 h 40 min 7.2
10 W 74 Control 02 h 45 min 5.7
11 M 69 CJD MM1 15 h 00 min 6.4
12 M 70 CJD MM1 N/A 4.7
13 W 64 CJD MM1 14 h 00 min 5.6
14 M 64 CJD MM1 14 h 00 min 4.7
15 M 77 CJD MM1 07 h 10 min 6,0
16 W 72 CJD MM1 08 h 00 min 7.0
17 M 78 CJD MM1 22 h 40 min 5.1
18 W 76 CJD VV2 05 h 00 min 5.5
19 M 65 CJD VV2 06 h 00 min 5.3
20 W 65 CJD VV2 07 h 15 min 5.4
21 W 72 CJD VV2 06 h 00 min 6.2
22 W 62 CJD VV2 08 h 45 min 4.7
23 M 71 CJD VV2 09 h 00 min 5.8
24 M 66 CJD VV2 05 h 00 min 6.8
25 M 52 CJD VV2 06 h 30 min 6.5
26 W 59 CJD VV2 09 h 00 min 6,7
27 W 67 CJD VV2 12 h 30 min 5.5
Table 2. TaqMan probes: gene identification, full name and
reference.
Gene Full name Reference
ALDH1L1 Aldehyde Dehydrogenase 1 Family Member
L1
Hs01003842_m1
AQP4 Aquaporin-4 Hs00242342_m1
CLDN11 Claudin 11 Hs00194440_m1
CNP 2ʹ,3ʹ-Cyclic Nucleotide 3ʹ Phosphodiesterase Hs00263981_m1
GALC Galactosylceramidase Hs00164660_m1
GFAP Glial fibrillary acidic protein Hs00909233_m1
GJA1 Gap junction alpha-1 protein/connexin-43 Hs00748445_s1
GJB1 Gap junction beta-1 protein/connexin-32 Hs00939759_s1
GJC2 Gap junction beta-2 protein/connexin-47 Hs00252713_s1
GJB6 Gap junction beta-6 protein/connexin-30 Hs00922742_s1
GUS-β β-glucuronidase Hs00939627_m1
MAG Myelin Associated Glycoprotein Hs01114387_m1
MAL Mal, T-Cell Differentiation Protein Hs00360838_m1
MBP Myelin Basic Protein Hs00921945_m1
MCT1 Solute Carrier Family 16 (Monocarboxylic
Acid Transporters), Member 1
Hs01560299_m1
MCT4 Solute Carrier Family 16 (Monocarboxylic
Acid Transporters), Member 4
Hs01006127_m1
MOBP Myelin-Associated Oligodendrocyte Basic
Protein
Hs01094434_m1
MOG Myelin Oligodendrocyte Glycoprotein Hs01555268_m1
MPC1 Mitochondrial Pyruvate Carrier 1 Hs00211484_m1
MYRF Myelin Regulatory Factor Hs00973739_m1
NG2 Neural/glial antigen 2 Hs00426981_m1
OLIG1 Oligodendrocyte Transcription Factor 1 Hs00744293_s1
OLIG2 Oligodendrocyte Lineage Transcription
Factor 2
Hs00377820_m1
PLP1 Proteolipid Protein 1 Hs00166914_m1
SLC1A2 Solute Carrier Family 1 (Glial High Affinity
Glutamate Transporter), Member 2
Hs01102423_m1
SLC2A1 Solute Carrier Family 2 (Facilitated Glucose
Transporter), Member 1
Hs01102423_m1
SOX-10 SRY-Box 10 Hs00366918_m1
UCP4 Mitochondrial Uncoupling Protein 4 Hs00188687_m1
UCP5 Mitochondrial Uncoupling Protein 5 Hs00605850_m1
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each sample minus the mean ΔCT of the population
of control samples.
Statistical analysis
The normality of distribution of fold change values was
510 analyzed with the Kolmogorov–Smirnov test. Pearson’s
correlation coefficient was used to assess a possible linear
association between two continuous quantitative vari-
ables. To determine the relationship between gene expres-
sion and RIN values according to pathologic variables, we
515 used the analysis of covariance (ANCOVA). Statistical
analysis of the expression data between groups was per-
formed using one-way analysis of variance (ANOVA)
followed by Tukey post-test or Kruskal-Wallis test fol-
lowed by Dunns post-hoc test when required using the
520 SPSS software (IBM Corp. Released 2013. IBM SPSS
Statistics for Windows, Version 21.0. Armonk, NY: IBM
Corp.). Outliers were detected using the GraphPad soft-
ware QuickCalcs (P < 0.05). All data were expressed as
mean values ± SEM. Differences between controls and
525 CJD MM1 or CJD VV2 were considered statistically sig-
nificant at * P < 0.05, ** P < 0.01, *** P < 0.001; and set at $
P < 0.05 and $$ P < 0.01when comparing CJD MM1 and
CJD VV2.
Immunohistochemistry
530 De-waxed sections, 4 microns thick, were processed for
immunohistochemistry (control n = 8; CJD MM1 n = 6;
CJD VV2 n = 2). The sections were boiled in citrate buffer
(20min) to retrieve tau antigenicity. Endogenous perox-
idases were blocked by incubation in 10% methanol-1%
535 H2O2 solution (15min) followed by 3% normal horse
serum solution. Then the sections were incubated at 4ºC
overnight with one of the primary antibodies against glial
fibrillary acidic protein (GFAP) (rabbit polyclonal, used at
1:500, Dako, Glostrup, DK), Olig-2 (rabbit polyclonal,
540 used at 1:500, Abcam, Cambridge, UK), aquaporine 4
(AQP4) (monoclonal, used at 1:400, Sigma, St Louis,
Missouri, USA), solute carrier family 1 member 2
(GLT1) (guinea pig used at 1:100, Merck-Millipore,
Billerica, MA, USA), mitochondrial pyruvate carrier 1
545 (MPC1) MPC1) (polyclonal, used at 1:100, Cell
Signaling Technology, Danvers, MA, USA), mitochon-
drial uncoupled protein 5 (UCP5) (polyclonal, used at
1:10, Novus Biological, Littleton, CO, USA), solute carrier
family 2 member 1 (GLUT1) (polyclonal, used at 1:100,
550 Abcam, Cambridge, CB, UK) and solute carrier family 16
member 1 (MCT1) (monoclonal, used at 1:50, Sigma, St
Louis, Missouri, USA). Following incubation with
Following incubation with the primary antibody, the sec-
tions were incubated with EnVision + system peroxidase
555(Dako, DK) for 30min at room temperature. The perox-
idase reaction was visualized with diaminobenzidine and
H2O2. Control of the immunostaining included omission
of the primary antibody; no signal was obtained following
incubation with only the secondary antibody. Peptides for
560pre-absorption studies were not available.
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